We Claim:

1. ~~A method of treating a patient infected with SARS-CoV-2 comprising administering to the patient in need of such treatment a therapeutically effective amount~~ Use of tofacitinib or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of SARS-CoV-2, wherein a therapeutically effective amount of the tofacitinib or the pharmaceutically acceptable salt thereof is to be administered to a patient infected with SARS-CoV-2.

2. ~~A method of treating a patient infected with SARS-CoV-2 comprising administering to the patient in need of such treatment 5 mgs~~ Use of tofacitinib or a pharmaceutically acceptable salt thereof~~BID or~~ in the manufacture of a medicament for the treatment of SARS-CoV-2, wherein 5 mgs of tofacitinib BID or an equivalent amount of tofacitinib in the form of ~~a~~ the pharmaceutically acceptable salt thereof is to be administered to a patient infected with SARS-CoV-2.

3. ~~A method of treating a patient infected with SARS-CoV-2 comprising administering to the patient in need of such treatment 10 mgs~~ Use of tofacitinib or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of SARS-CoV-2, wherein 10 mgs of tofacitinib BID or an equivalent amount of tofacitinib in the form of ~~a~~ the pharmaceutically acceptable salt thereof is to be administered to a patient infected with SARS-CoV-2.

4. ~~A method of treating a patient infected with SARS-CoV-2 comprising administering to the patient in need of such treatment 11 mgs~~ Use of tofacitinib or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of SARS-CoV-2, wherein 11 mgs of tofacitinib QD or an equivalent amount of tofacitinib in the form of ~~a~~ the pharmaceutically acceptable salt thereof is to be administered to a patient infected with SARS-CoV-2.

5. ~~A method of treating a patient infected with SARS-CoV-2 comprising administering to the patient in need of such treatment~~ Use of tofacitinib or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of SARS-CoV-2, wherein a therapeutically effective amount of tofacitinib, or ~~a~~ an equivalent amount of tofacitinib in the form of the pharmaceutically acceptable salt thereof~~,~~ is to be administered to a patient infected with SARS-CoV-2 to reduce ~~wherein~~ IL-6 levels ~~are reduced~~ by at least 20%.

6. ~~A method of treating a patient infected with SARS-CoV-2 comprising administering orally to the patient in need of such treatment~~ Use of tofacitinib or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of SARS-CoV-2, wherein 2.5-15 mgs of tofacitinib, or an equivalent amount of tofacitinib in the form of ~~a~~ the pharmaceutically acceptable salt thereof is to be administered orally to a patient infected with SARS-CoV to reduce~~, wherein~~ IL-6 levels ~~are reduced~~ by at least 20%.

7. ~~A method of treating a patient infected with SARS-CoV-2 comprising administering orally to the patient in need of such treatment~~ Use of tofacitinib or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of SARS-CoV-2, wherein 10 mgs of tofacitinib BID, or an equivalent amount of tofacitinib in the form of ~~a~~ the pharmaceutically acceptable salt thereof is to be administered orally to a patient infected with SARS-CoV to reduce~~, wherein~~ IL-6 levels ~~are reduced~~ by at least 20%.

8. ~~A method of treating a patient infected with SARS-CoV-2 comprising administering orally to the patient in need of such treatment~~ Use of tofacitinib or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of SARS-CoV-2, wherein 10 mgs of tofacitinib BID, or an equivalent amount of

tofacitinib in the form of ~~a~~ the pharmaceutically acceptable salt thereof is to be administered orally to a patient infected with SARS-CoV to reduce~~, wherein~~ IL-6 levels ~~are reduced~~ by at least 50%.

9. ~~A method of treating a patient infected with SARS-CoV-2 comprising administering orally to the patient in need of such treatment~~Use of tofacitinib or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of SARS-CoV-2, wherein 10 mgs of tofacitinib BID, or an equivalent amount of tofacitinib in the form of ~~a~~ the pharmaceutically acceptable salt thereof is to be administered orally to a patient infected with SARS-CoV to reduce~~, wherein~~ IL-6 levels ~~are reduced~~ by at least 75%.

10. ~~A method of treating a patient infected with SARS-CoV-2 comprising administering orally to the patient in need of such treatment~~ Use of tofacitinib or a pharmaceutically acceptable salt thereofin the manufacture of a medicament for the treatment of SARS-CoV-2, wherein 10 mgs of tofacitinib BID, or an equivalent amount of tofacitinib in the form of ~~a~~ the pharmaceutically acceptable salt thereof is to be administered orally to a patient infected with SARS-CoV to reduce~~, wherein~~ IL-6 and IL-8 levels ~~are~~ each ~~reduced~~ by at least 35%.

11. ~~A method of treating a patient infected with SARS-CoV-2 comprising administering orally to the patient in need of such treatment~~ Use of tofacitinib or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of SARS-CoV-2, wherein 10 mgs of tofacitinib BID, or an equivalent amount of tofacitinib in the form of ~~a~~ the pharmaceutically acceptable salt thereof is to be administered orally to a patient infected with SARS-CoV to reduce~~, wherein~~ IL-6, IL-8, and TNFα levels ~~are~~ each ~~reduced~~ by at least 35%.

12. ~~A method of treating a patient infected with SARS-CoV-2 comprising administering orally to the patient in need of such treatment~~ Use of tofacitinib or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of SARS-CoV-2, wherein 10 mgs of tofacitinib BID or an equivalent amount of tofacitinib in the form of the pharmaceutically acceptable salt thereof is to be administered orally to a patient infected with SARS-CoV-2 to reduce~~, wherein~~ IL-6, IFNα, IFNβ, and TNFα levels ~~are~~ each ~~reduced~~ by at least 35%.

13. ~~A method of treating a patient infected with SARS-CoV-2 comprising administering orally to the patient in need of such treatment~~ Use of tofacitinib or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of SARS-CoV-2, wherein 10 mgs of tofacitinib BID, or an equivalent amount of tofacitinib in the form of ~~a~~ the pharmaceutically acceptable salt thereof is to be administered orally to a patient infected with SARS-CoV-2 to reduce~~, wherein~~ IFNγ, IL-6, IL-15, IL-21, and IL-27 levels ~~are~~ each ~~reduced~~ by at least 20%.

14. ~~A method of treating a patient infected with SARS-CoV-2 comprising administering orally to the patient in need of such treatment~~ Use of tofacitinib or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of SARS-CoV-2, wherein 10 mgs of tofacitinib BID, or an equivalent amount of tofacitinib in the form of ~~a~~ the pharmaceutically acceptable salt thereof is to be administered orally to a patient infected with SARS-CoV-2 to reduce~~, wherein~~ IFNα, IFNγ, IL-2, IL4, IL-6, IL-7, IL-10, IL-12, IL13, IL-15, and IL-23 levels ~~are~~ each ~~reduced~~ by at least 20%.

15. ~~A method of treating a patient infected with SARS-CoV-2 comprising administering to the patient in need of such treatment~~ Use of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide ~~PF-06650833~~ or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of SARS-CoV-2, wherein 400 mgs of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide~~PF-06650833~~ QD or an equivalent amount of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide~~PF-06650833~~ in the form of ~~a~~ the pharmaceutically acceptable salt thereof is to be administered to a patient infected with SARS-CoV-2.

16. ~~A method of treating a patient infected with SARS-CoV-2 comprising administering to the patient in need of such treatment~~ Use of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide ~~PF-06650833~~ or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of SARS-CoV-2, wherein 200 mgs of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide~~PF-06650833~~ Q6H or an equivalent amount of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide~~PF-06650833~~ in the form of ~~a~~ the pharmaceutically acceptable salt thereof is to be administered to a patient infected with SARS-CoV-2.

17. ~~A method of treating a patient infected with SARS-CoV-2 comprising administering to the patient in need of such treatment a therapeutically effective amount~~ Use of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide~~PF-06650833~~, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of SARS-CoV-2, wherein a therapeutically effective amount of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide or an equivalent amount of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide in the form of the pharmaceutically acceptable salt thereof is to be administered to a patient infected with SARS-CoV-2 to reduce~~, wherein~~ IL-6 levels ~~are reduced~~ by at least 75%.

18. ~~A method of treating a patient infected with SARS-CoV-2 comprising administering to the patient in need of such treatment~~ Use of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide ~~PF-06650833~~ or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of SARS-CoV-2, wherein 100-800 mgs of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide~~PF-06650833~~, or an equivalent amount of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide~~PF-06650833~~ in the form of the~~a~~ pharmaceutically acceptable salt thereof is to be administered to a patient infected with SARS-CoV-2 to reduce~~, wherein~~ IL-6 levels ~~are reduced~~ by at least 75%.

19. ~~A method of treating a patient infected with SARS-CoV-2 comprising administering orally to the patient in need of such treatment~~ Use of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide ~~PF-06650833~~ or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of SARS-CoV-2, wherein 400 mgs of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide ~~PF-06650833~~ QD, or an equivalent amount of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide ~~PF-06650833~~ in the form of ~~a~~ the pharmaceutically acceptable salt thereof is to be administered orally to a patient infected with SARS-CoV-2 to reduce~~, wherein~~ IL-6 levels ~~are reduced~~ by at least 75%.

20. ~~A method of treating a patient infected with SARS-CoV-2 comprising administering to the patient in need of such treatment~~ Use of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide ~~PF-06650833~~ or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of SARS-CoV-2, wherein 200 mgs of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide~~PF-06650833~~ Q6H, or an equivalent amount of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide~~PF-06650833~~ in the form of ~~a~~ the pharmaceutically acceptable salt thereof is to be administered to a patient infected with SARS-CoV-2 to reduce~~, wherein~~ IL-6 levels ~~are reduced~~ by at least 75%.

21. ~~A method of treating a patient infected with SARS-CoV-2 comprising administering orally to the patient in need of such treatment~~ Use of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide ~~PF-06650833~~ or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of SARS-CoV-2, wherein 400 mgs of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide~~PF-06650833~~ QD, or an equivalent amount of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide~~PF-06650833~~ in the form of ~~a~~ the pharmaceutically acceptable salt thereof is to be administered orally to a patient infected with SARS-CoV-2 to reduce~~, wherein~~ IL-6 IL-1, and TNFα levels ~~are~~ each ~~reduced~~ by at least 20%.

22. ~~A method of treating a patient infected with SARS-CoV-2 comprising administering to the patient in need of such treatment~~ Use of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide ~~PF-06650833~~ or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of SARS-CoV-2, wherein 200 mgs of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide~~PF-06650833~~ Q6H, or an equivalent amount of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide

~~PF-06650833~~ in the form of ~~a~~ the pharmaceutically acceptable salt thereof is to be administered to a patient infected with SARS-CoV-2 to reduce~~, wherein~~ IL-6 IL-1, and TNFα levels ~~are~~ each ~~reduced~~ by at least 20%.

23. ~~A method of treating a patient infected with SARS-CoV-2 comprising administering orally to the patient in need of such treatment~~ Use of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide ~~PF-06650833~~ or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of SARS-CoV-2, wherein 400 mgs of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide~~PF-06650833~~ QD, or an equivalent amount of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide~~PF-06650833~~ in the form of ~~a~~ the pharmaceutically acceptable salt thereof is to be administered orally to a patient infected with SARS-CoV-2 to reduce~~, wherein~~ IL-6 IL-1, TNFα, IFNα, and IFNy levels ~~are~~ each ~~reduced~~ by at least 20%.

24. ~~A method of treating a patient infected with SARS-CoV-2 comprising administering to the patient in need of such treatment~~ Use of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide ~~PF-06650833~~ or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of SARS-CoV-2, wherein 200 mgs of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide~~PF-06650833~~ Q6H, or an equivalent amount of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide~~PF-06650833~~ in the form of ~~a~~ the pharmaceutically acceptable salt thereof is to be administered to a patient infected with SARS-CoV-2 to reduce~~, wherein~~ IL-6 IL-1, TNFα, IFNα, and IFNy levels ~~are~~ each ~~reduced~~ by at least 20%.

25. ~~A method of treating a patient infected with SARS-CoV-2 comprising administering orally to the patient in need of such treatment~~ Use of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide ~~PF-06650833~~ or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of SARS-CoV-2, wherein 400 mgs of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide~~PF-06650833~~ QD, or an equivalent amount of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide~~PF-06650833~~ in the form of ~~a~~ the pharmaceutically acceptable salt thereof is to be administered orally to a patient infected with SARS-CoV-2 to reduce~~, wherein~~ IL-6 IL-1, TNFα, IFNα, IFNy, and CXCL8 levels ~~are~~ each ~~reduced~~ by at least 20%.

26. ~~A method of treating a patient infected with SARS-CoV-2 comprising administering to the patient in need of such treatment~~ Use of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide ~~PF-06650833~~ or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of SARS-CoV-2, wherein 200 mgs of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide~~PF-06650833~~ Q6H, or an equivalent amount of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide~~PF-06650833~~ in the form of ~~a~~ the pharmaceutically acceptable salt thereof is to be administered to a patient infected with SARS-CoV-2 to reduce~~, wherein~~ IL-6 IL-1, TNFα, IFNα, IFNy, and CXCL8 levels ~~are~~ each ~~reduced~~ by at least 20%.

27. ~~A method of treating a patient infected with SARS-CoV-2 comprising administering orally to the patient in need of such treatment~~ Use of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide ~~PF-06650833~~ or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of SARS-CoV-2, wherein 400 mgs of 1-(((2S,3S,4S)-3-

Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide~~PF-06650833~~ QD, or an equivalent amount of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide~~PF-06650833~~ in the form of ~~a~~ the pharmaceutically acceptable salt thereof is to be administered orally to a patient infected with SARS-CoV-2 to reduce~~, wherein~~ CRP levels ~~are reduced~~ by at least 50% and ~~wherein~~ IL-6 IL-1, TNFα, IFNα, IFNy, and CXCL8 levels ~~are~~ each ~~reduced~~ by at least 20%.

28. ~~A method of treating a patient infected with SARS-CoV-2 comprising administering to the patient in need of such treatment~~ Use of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide ~~PF-06650833~~ or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of SARS-CoV-2, wherein 200 mgs of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide~~PF-06650833~~ Q6H, or an equivalent amount of 1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide~~PF-06650833~~ in the form of ~~a~~ the pharmaceutically acceptable salt thereof is to be administered to a patient infected with SARS-CoV-2 to reduce~~, wherein~~ CRP levels ~~are reduced~~ by at least 50% and ~~wherein~~ IL-6 IL-1, TNFα, IFNα, IFNy, and CXCL8 levels ~~are~~ each ~~reduced~~ by at least 20%.